Amgen’s New Obesity Drug: Will Amgen Stock Skyrocket Through FDA Trials?

Amgen’s New Obesity Drug: Will Amgen Stock Skyrocket Through FDA Trials?

So far, all signals point to a resounding yes. Amgen’s obesity drug, AMG 133, completed a successful phase I trial, which helped lift the company’s stock price. Here’s what investors need to know.